Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10822350 | 0.78 | — | — | |
| SCHEMBL11748204 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL5886098 | 0.73 | — | — | |
| SCHEMBL13043984 | 0.72 | TSHR (0.30) | TSHR | |
| SCHEMBL306131 | 0.71 | BCHE (0.31) | TSHR | |
| SCHEMBL935573 | 0.69 | — | — | |
| SCHEMBL16816655 | 0.68 | MVD (0.34) | — | |
| SCHEMBL9833152 | 0.68 | KMT2A (0.42) | TSHR | |
| SCHEMBL11149946 | 0.67 | — | — | |
| SCHEMBL31536717 | 0.67 | CHRNB2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-7151182-B2 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-12-19 | — | — | US | disclosed |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| EP-1280795-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001032652-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | TSHR 4298/4885 |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | TSHR 4418/4885 |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, CPS1 | TSHR 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.